Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06183931

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM — DepleTTR-CM  

Transthyretin Amyloid Cardiomyopathy Clinical Trial

Official title:
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Clinical Trial Summary

The primary objective of this study is to assess the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the composite endpoint of all-cause mortality (ACM) and total cardiovascular (CV) clinical events.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06183931
Study type Interventional
Source Alexion Pharmaceuticals, Inc.
Contact Alexion Pharmaceuticals, Inc. (Sponsor)
Phone 1-855-752-2356
Email clinicaltrials@alexion.com
Status Recruiting
Phase Phase 3
Start date January 11, 2024
Completion date October 25, 2028
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Active, not recruiting NCT06257485 - Bronx Transthyretin Amyloid Cardiomyopathy Database
Recruiting NCT06086353 - A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India
Active, not recruiting NCT06321523 - A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Completed NCT05233163 - SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy Phase 4
Not yet recruiting NCT06101108 - Early Diagnosis of Age-Linked CArdiac TransThyRetin Amyloidosis by Selective Screening in Spinal Stenosis Surgery
Completed NCT04814186 - A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Phase 4
Recruiting NCT04899180 - Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis Early Phase 1
Recruiting NCT05259072 - carDIo-ttranSSfOrm nucLEar Imaging Study Phase 3
Recruiting NCT06328075 - Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis
Recruiting NCT06291805 - Phenotyping and Characterization of wtATTR-CM (TRACE 1)
Terminated NCT04424914 - Global Prevalence of ATTR-CM in Participants With HFpEF N/A
Recruiting NCT06194825 - EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy Phase 3
Recruiting NCT06372301 - Dobutamine Stress Echocardiography in LF/LG Aortic Stenosis and Wild-type Transthyretin Amyloid Cardiomyopathy N/A